MedTrace Logo

Role of Early Versus Late Switch to Lapatinib-Capecitabine

NCT01357863 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2018-09-14

No results posted yet for this study

Summary

The study will be conducted as a multicenter prospective observational cohort study, trying to cover almost all Brazilian States, in a population of ErbB2 positive metastatic breast cancer patients, whose disease has progressed after trastuzumab-containing regimen, comparing outcomes in two groups: Group 1: patients receiving Lapatinib-capecitabine immediately after 1st Trastuzumab progression (second line treatment), and Group 2: patients receiving Lapatinib-capecitabine after 2 or more lines of treatment after 1st trastuzumab progression (third line or greater).

Conditions

Interventions

DRUG

Treatment

Patients treated with Lapatinib-capecitabine after Trastuzumab progression

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-15
Primary Completion
2010-12-13
Completion
2010-12-13

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01357863 on ClinicalTrials.gov